Patient Management

Chronic liver disease (CLD) causes approximately two million deaths annually and presents a major global health burden. Because most severe outcomes—like liver failure, portal hypertension, and hepatocellular carcinoma—occur...

Patient Management Guidelines

Guidance From Medscape

Expert opinions, case studies, quizzes, and more can be found at Medscape’s new portal for clinicians who treat metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.

Managing Metabolic Dysfunction-associated Steatotic Liver and Metabolic Dysfunction-associated Steatohepatitis

The Journal of Hepatology provides detailed information for clinicians who treat patients who have been diagnosed with liver diseases formerly known as nonalcoholic steatohepatitis (NASH).

American Association for the Study of Liver Diseases (AASLD) Guidelines

AASLD offers guidelines that are current and revised regularly by a committee of experts in the field of hepatology.

Articles

Systemic Impacts of MASLD on Heart-related Diseases

This review provided a comprehensive analysis of the extrahepatic manifestations of metabolic dysfunction-associated steatohepatitis (MASH), focusing on chronic diseases related...
Chantil D. Jeffreys,
CURATED BY:
Chantil D. Jeffreys,
FNP, DNP, JD

Challenges of Liver Transplantation for MASLD

Liver transplantation (LT) for metabolic dysfunction-associated steatotic liver disease (MASLD) is challenging due to high comorbidity rates, including obesity, diabetes,...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Genetic Risk Factors for NASH-Related Hepatocellular Carcinoma

This study aimed to identify genetic risk factors driving the progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C
Supportive doctor soothing a worried overweight patient, discussing test result in emergency room. Illnesses and diseases in middle-aged men's health. Compassionate physician supporting stressed

MASH Risk Guide for At-Risk Patients

This guide is designed for patients at risk for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH)....
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

GLP-1 Agonists’ Potential for Fibrosis Regression

In a recent review, researchers examined the molecular and clinical effects of glucagon-like peptide 1 (GLP-1) receptor agonists in treating...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN

MASLD: The Growing Need for Early Intervention

MASLD (metabolic-associated steatotic liver disease) is the most common chronic liver disease in the US, affecting an estimated 31% of...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN
Share